OBJECTIVES: IL-37 is an anti-inflammatory cytokine involved in inflammatory and autoimmune diseases. We aimed to investigate the association between IL-37 genetic variants, IL-37 plasma levels, and various clinical phases of gout. METHODS: The study included a control group with no history of primary hyperuricemia/gout, (n = 50), asymptomatic hyperuricemia (n = 74), intercritical gout (n = 200), acute gouty flare (n = 18), and chronic tophaceous gout (n = 30). Plasma IL-37 was analysed using enzyme-linked immunosorbent assay. All coding regions and intron-exon boundaries of IL-37 and exons 1-5 were amplified and sequenced. RESULTS: Plasma levels of IL-37 were significantly higher in asymptomatic hyperuricemic (p = 0.045), intercritical gout (p = 0.001), and chronic tophaceous gout (p = 0.021) cohorts when compared to control group. The levels of IL-37 in patients with acute gouty flare were comparable to control group (p = 0.061). We identified 15 genetic variants of IL-37: eight intron (rs2708959, rs2723170, rs2708958, rs2723169 rs2466448, rs3811045, rs3811048, rs2708944) and seven non-synonymous allelic variants (rs3811046, rs3811047, rs2708943, rs2723183, rs2723187, rs2708947, rs27231927), of which rs2708959 showed an over-presentation in gouty and acute flare cohorts (p = 0.003 and 0.033, respectively) compared to European population (minor allelic frequency MAF = 0.05) but not in control and hyperuricemic cohorts (p/MAF = 0.17/0.08 and 0.71/0.05, respectively).. On the contrary, rs3811045, rs3811046, rs3811047, and rs3811048 were underrepresented among individuals with tophaceous gout (MAF = 0.57) compared to European MAF 0.70-0.71, but not compared to the control cohort (MAF = 0.67). CONCLUSIONS: We demonstrated the up-regulation of IL-37 levels across the clinical phases of gout: asymptomatic hyperuricemia, intercritical, and chronic tophaceous gout compared to control. Moreover, 15 genetic variants of IL-37 were identified and their associations with the clinical variants of gout were evaluated.

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Probability and Mathematical Statistics Faculty of Mathematics and Physics Charles University Prague Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Na Slupi 4 128 50 Prague 2 Czech Republic

Zobrazit více v PubMed

Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout Nat Rev Dis Primers. 2019;5:69. doi: 10.1038/s41572-019-0115-y. PubMed DOI

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77:1048–1052. doi: 10.1136/annrheumdis-2017-212288. PubMed DOI

Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88:105092. doi: 10.1016/j.jbspin.2020.105092. PubMed DOI

Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018;281:179–190. doi: 10.1111/imr.12605. PubMed DOI

Chen B, Huang K, Ye L, Li Y, Zhang J, Zhang J, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med. 2015;13:36. doi: 10.1186/s12967-015-0394-3. PubMed DOI PMC

Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med. 2014;12:69. doi: 10.1186/1479-5876-12-69. PubMed DOI PMC

Yuan ZC, Wang JM, Huang AF, Su LC, Li SJ, Xu WD. Elevated expression of interleukin-37 in patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22:1123–1129. doi: 10.1111/1756-185X.13539. PubMed DOI

Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014–1022. doi: 10.1038/ni.1944. PubMed DOI PMC

Zeng M, Dang W, Chen B, Qing Y, Xie W, Zhao M, et al. IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response. Clin Rheumatol. 2016;35:2251–2258. doi: 10.1007/s10067-015-3109-5. PubMed DOI

Ding L, Li H, Sun B, Wang T, Meng S, Huang Q, et al. Elevated interleukin-37 associated with tophus and pro-inflammatory mediators in Chinese gout patients. Cytokine. 2021;141:155468. doi: 10.1016/j.cyto.2021.155468. PubMed DOI

Liu L, Xue Y, Zhu Y, Xuan D, Yang X, Liang M, et al. Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout. Arthritis Res Ther. 2016;18:268. doi: 10.1186/s13075-016-1167-y. PubMed DOI PMC

Klück V, van Deuren RC, Cavalli G, Shaukat A, Arts P, Cleophas MC, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis. 2020;79:536–544. doi: 10.1136/annrheumdis-2019-216233. PubMed DOI

Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895–900. doi: 10.1002/art.1780200320. PubMed DOI

Stiburkova B, Krijt J, Vyletal P, Bartl J, Gerhatova E, Korinek M, et al. Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I. Clin Chim Acta. 2012;413:93–99. doi: 10.1016/j.cca.2011.08.038. PubMed DOI

Toyoda Y, Mančíková A, Krylov V, Morimoto K, Pavelcová K, Bohatá J, et al. Functional characterization of clinically-relevant rare variants in ABCG2 identified in a gout and hyperuricemia cohort. Cells. 2019;8:363. doi: 10.3390/cells8040363. PubMed DOI PMC

Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B. Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and gout. J Clin Med. 2020;9:2510. doi: 10.3390/jcm9082510. PubMed DOI PMC

Santarelli DM, Vincent FB, Rudloff I, Nold-Petry CA, Nold MF, Russo MA. Circulating interleukin-37 levels in healthy adult humans - establishing a reference range. Front Immunol. 2021;12:708425. doi: 10.3389/fimmu.2021.708425. PubMed DOI PMC

Pei B, Xu S, Liu T, Pan F, Xu J, Ding C. Associations of the IL-1F7 gene polymorphisms with rheumatoid arthritis in Chinese Han population. Int J Immunogenet. 2013;40:199–203. doi: 10.1111/iji.12007. PubMed DOI

Pan F, Liao F, Xia G, Ge R, Mei Y, Tang X, et al. Association of IL-1F7 gene with susceptibility to human leukocyte antigen-B27 positive ankylosing spondylitis in Han Chinese population. Clin Chim Acta. 2010;411:124–126. doi: 10.1016/j.cca.2009.10.014. PubMed DOI

Ge R, Pan F, Liao F, Xia G, Mei Y, Shen B, et al. Analysis on the interaction between IL-1F7 gene and environmental factors on patients with ankylosing spondylitis: a case-only study. Mol Biol Rep. 2011;38:2281–2284. doi: 10.1007/s11033-010-0359-9. PubMed DOI

Ahmed AA, Ad’hiah AH. Interleukin-37 gene polymorphism and susceptibility to coronavirus disease 19 among Iraqi patients. Meta Gene. 2022;31:100989. PubMed PMC

Ali ZA, Mankhi AA, Ad’hiah AH. Interleukin-37 gene polymorphism and susceptibility to pulmonary tuberculosis among Iraqi patients. Indian J Tuberc. 2022;69:191–200. PubMed

Zhang XY, Zuo Y, Li C, Tu X, Xu HJ, Guo JP, et al. IL1F7 gene polymorphism is not associated with rheumatoid arthritis susceptibility in the Northern Chinese Han population: a case-control study. Chin Med J (Engl) 2018;131:171–179. doi: 10.4103/0366-6999.222340. PubMed DOI PMC

Mookherjee S, Banerjee D, Chakraborty S, Mukhopadhyay I, Sen A, Ray K. Evaluation of the IL1 gene cluster single nucleotide polymorphisms in primary open-angle glaucoma pathogenesis. Genet Test Mol Biomarkers. 2016;20:633–636. doi: 10.1089/gtmb.2015.0344. PubMed DOI

Allam G, Gaber AM, Othman SI, Abdel-Moneim A. The potential role of interleukin-37 in infectious diseases. Int Rev Immunol. 2020;39:3–10. doi: 10.1080/08830185.2019.1677644. PubMed DOI

Cirelli T, Nepomuceno R, Orrico SRP, Rossa C, Jr, Cirelli JA, North KE, et al. Validation in a Brazilian population of gene markers of periodontitis previously investigated by GWAS and bioinformatic studies. J Periodontol. 2021;92:689–703. doi: 10.1002/JPER.20-0126. PubMed DOI

Yan N, Meng S, Song RH, Qin Q, Wang X, Yao Q, et al. Polymorphism of IL37 gene as a protective factor for autoimmune thyroid disease. J Mol Endocrinol. 2015;55:209–218. doi: 10.1530/JME-15-0144. PubMed DOI

Lin XY, Guo XJ, He YZ, Hou SF, Zhu HB, Cheng Y, et al. Association between interleukin 37 (rs3811047) polymorphism and multiple autoimmune diseases in a Chinese population: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2018;97:e0386. doi: 10.1097/MD.0000000000010386. PubMed DOI PMC